Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer
January 22 2024 - 11:45AM
Transgene Further Strengthens Management Team with Appointment of
James Wentworth as Chief Business Officer
Strasbourg, France, January 22, 2024,
5:45 p.m. CET – Transgene (Euronext Paris: TNG), a
biotech company that designs and develops virus-based
immunotherapies for the treatment of cancer, is pleased to announce
the appointment of James Wentworth, PhD, MBA, as Chief Business
Officer (CBO) and member of the executive management team,
effective immediately. Dr. Wentworth will be
responsible for developing, leading, and implementing Transgene’s
business, corporate development and partnering
strategies.
Alessandro Riva, MD,
Chairman and CEO of Transgene, comments: “I am very
pleased to welcome James, at a pivotal time for Transgene as we
seek to develop novel cancer immunotherapies including an
individualized neoantigen cancer vaccine. Our business development
strategy will be crucial to achieving our goals, and James’
significant experience and knowledge will be invaluable as we
continue to build our strong track record of successful
collaborations.”
Dr. Wentworth brings over fifteen years’
experience working in the pharma and biotech industry. He joins
Transgene following increasing responsibility spanning business
development, strategy and commercial roles. Most recently, James
was Director, Business Development and Strategy at Adaptimmune, a
NASDAQ-listed biotechnology company focused on developing T-cell
receptor (TCR)-based cell therapies for solid tumors. His
responsibilities included strategic pharma partnering,
collaborations and transactions, corporate development projects,
commercial strategy development and he also led the company’s
competitive intelligence function.
Prior to Adaptimmune, James worked with
pre-commercial Biotech companies at inVentiv Health (now Syneos
Health) and held strategic roles at Shire, contributing to product
development, post M&A integration, and managing commercial
launches in European markets for ViroPharma Europe.
James holds a BSc Hons degree in Pharmacology
and a PhD in Pharmacology both from the University of Bristol and
an MBA from the International Institute for Management Development
(IMD), Lausanne, Switzerland.
Dr. James Wentworth, Chief Business
Officer, said: “It is an honor to be joining Transgene at
this exciting time and to work alongside the outstanding executive
team to contribute to Transgene’s success. The company has achieved
many important milestones over the past year, and I am excited to
help deliver its growth strategy through further partnerships and
collaborations. Transgene is uniquely positioned with its
innovative technology and platform offering, and together with the
promising emerging data for its portfolio of clinical-stage
immunotherapies, has the potential to address major medical needs
in the treatment of solid tumors and to transform patients’
lives.”
***
About Transgene
Transgene (Euronext: TNG) is a biotechnology
company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells. The Company’s clinical-stage
programs consist of a portfolio of therapeutic vaccines and
oncolytic viruses: TG4050, the first individualized therapeutic
vaccine based on the myvac® platform, TG4001 for the treatment of
HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic
viruses based on the Invir.IO® viral backbone. With Transgene’s
myvac® platform, therapeutic vaccination enters the field of
precision medicine with a novel immunotherapy that is fully
tailored to each individual. The myvac® approach allows the
generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC. With its
proprietary platform Invir.IO®, Transgene is building on its viral
vector engineering expertise to design a new generation of
multifunctional oncolytic viruses. Additional information about
Transgene is available at: www.transgene.frFollow us on social
media: X (previously-Twitter): @TransgeneSA – LinkedIn:
@Transgene
Contacts
Transgene:Lucie LarguierVP,
Corporate Communications &
IR+33 (0)3 88 27 91 04investorrelations@transgene.fr |
Media: MEDiSTRAVA Frazer Hall
/Sylvie Berrebi+44
(0)203 928 6900transgene@medistrava.com |
Disclaimer
This press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Universal Registration Document, available on the
AMF website (http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made, and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
- 20240122_Transgene_Appoints-JWentworth_CBO_EN
Transgene (EU:TNG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Transgene (EU:TNG)
Historical Stock Chart
From Jul 2023 to Jul 2024